Related Experiment Videos

GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer

Pierluigi Tricoci1, L Kristin Newby

  • 1Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina 27705, USA. trico001@dcri.duke.edu

Cardiology in Review
|February 19, 2008
PubMed

Insights

Glycoprotein IIb-IIIa inhibitors benefit high-risk acute coronary syndrome patients. Upstream initiation upon admission may improve outcomes compared to delayed treatment before percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Glycoprotein IIb-IIIa inhibitors are crucial for non-ST-elevation acute coronary syndromes with high-risk features.
  • Current guidelines recommend their use but lack specific timing guidance.
  • Emerging antiplatelet and antithrombotic agents complicate treatment strategies.

Purpose of the Study:

  • To evaluate the optimal timing for initiating Glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
  • To compare upstream versus delayed initiation strategies.

Main Methods:

  • Review of preliminary data on Glycoprotein IIb-IIIa inhibitor initiation timing.
  • Analysis of patient outcomes based on timing of administration (admission vs. catheterization lab).

Main Results:

  • Preliminary data suggest superior outcomes with upstream initiation of Glycoprotein IIb-IIIa inhibitors.
  • Delayed initiation in the catheterization laboratory may be less effective.

Conclusions:

  • Upstream initiation of Glycoprotein IIb-IIIa inhibitors appears beneficial for high-risk acute coronary syndrome patients.
  • Further research is needed to define optimal strategies amidst new drug availability.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...